A Comparative Clinical Study to Determine the Optimal Initial Therapy for Multiple Myeloma

PRAGMMATIC: A Comparative Clinical Trial to Determine the BEST Initial Therapy for Multiple Myeloma

This study evaluates the outcomes of patients undergoing initial therapy for multiple myeloma.

PRIMARY OBJECTIVE:

I. Compare the overall survival between bortezomib, lenalidomide and dexamethasone (VRd), daratumumab, lenalidomide and dexamethasone (DRd) and daratumumab, bortezomib, lenalidomide and dexamethasone (DVRd) used as initial therapy for patients with newly diagnosed MM.

OUTLINE: This is an observational study.

Patients have their medical records reviewed on study.

Inclusion Criteria:

• Previously untreated active multiple myeloma starting a new treatment for the disease with one of the three established treatment regimens: VRd (bortezomib, lenalidomide, dexamethasone), DRd (daratumumab lenalidomide dexamethasone), or DVRd (daratumumab, bortezomib, lenalidomide, and dexamethasone)
• No prior treatment for myeloma
• Not receiving concurrent treatment for another active malignancy
• No more than 3 months from start of treatment

Exclusion Criteria:

• Does not meet all inclusion criteria